Half-Year 2022 Financial Performance

Cell & Gene Financial and operational performance in H1 2022 344.m Sales (CHF) 77m CORE EBITDA (CHF) +23.4%¹ +75.0% 22.4% CORE EBITDA Margin Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) +6.3ppts - Lonza Cell and Gene Technologies: continued focus on scale up of late- stage clinical and commercial products Personalized Medicine: launch of second-generation instrument of Cocoon offering magnetic selection to improve cell purification. Commercialization of CocoonⓇ on track Bioscience: strong customer demand with expectation to maintain growth and profitability Excluding a one-time event, margin is broadly stable compared to H1 2021 CORE definition: See appendix 21

View entire presentation